
    
      OBJECTIVES: I. Assess the response to carboplatin (CBDCA) in patients with progressive
      low-grade gliomas. II. Assess the activity of CBDCA in stabilizing the growth of these
      tumors.

      OUTLINE: Single-Agent Chemotherapy. Carboplatin, CBDCA, NSC-241240.

      PROJECTED ACCRUAL: A total of 25 evaluable patients will be entered if there is at least 1
      response in the first 9 patients.
    
  